Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xencor, Inc. - Common Stock (NQ:XNCR)

11.61 +0.79 (+7.30%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Xencor, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Xencor to Host Third Quarter 2022 Financial Results Webcast and Conference Call on November 7, 2022
From Xencor, Inc.
Via Business Wire
News headline image
Xencor to Present Seven Posters on Multiple Clinical Trials and Research-stage Programs at the SITC Annual Meeting
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Appoints Nancy Valente, M.D., to Board of Directors
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Reports Second Quarter 2022 Financial Results
From Xencor, Inc.
Via Business Wire
News headline image
Xencor to Host Second Quarter 2022 Financial Results Webcast and Conference Call on August 3, 2022
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Reports First Quarter 2022 Financial Results
From Xencor, Inc.
Via Business Wire
News headline image
Xencor to Host First Quarter 2022 Financial Results Webcast and Conference Call on May 5, 2022
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Presents Data from Multiple Preclinical XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Reports Fourth Quarter and Full Year 2021 Financial Results
From Xencor, Inc.
Via Business Wire
News headline image
Xencor to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 23, 2022
From Xencor, Inc.
Via Business Wire
News headline image
Xencor to Present at Upcoming Investor Conferences
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Highlights 2022 Corporate Priorities and Portfolio Milestones
From Xencor, Inc.
Via Business Wire
News headline image
Xencor to Present at the H.C. Wainwright Bioconnect Virtual Conference
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting
From Xencor, Inc.
Via Business Wire
News headline image
Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor
From Xencor, Inc.
Via Business Wire
News headline image
Xencor to Present at Upcoming Investor Conferences
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Presents Updated Data from the Phase 1 Study of Vudalimab, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody Programs and IL-12 Cytokine, XmAb662, at the SITC Annual Meeting
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Reports Third Quarter 2021 Financial Results and Announces Encouraging Preliminary Data from Ongoing Phase 1 Study of Potency-reduced IL15-Fc Cytokine, XmAb306
From Xencor, Inc.
Via Business Wire
News headline image
Xencor to Present Data from the Phase 1 Study of Plamotamab in B-Cell Malignancies at the American Society of Hematology Annual Meeting
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Presents Clinical Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium
From Xencor, Inc.
Via Business Wire
News headline image
Xencor to Present at Upcoming Investor Conferences
From Xencor, Inc.
Via Business Wire
News headline image
Xencor to Host Third Quarter 2021 Financial Results Webcast and Conference Call on November 8, 2021
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Enters Global Collaboration and License Agreement With Janssen to Advance Plamotamab and XmAb CD28 Bispecific Antibody Combinations for the Treatment of Patients With B-Cell Malignancies
From Xencor, Inc.
Via Business Wire
News headline image
Xencor to Present Data from the Phase 1 Study of Vudalimab (XmAb®717) and Four Research Programs at the SITC Annual Meeting
From Xencor, Inc.
Via Business Wire
News headline image
Xencor to Present at the 2021 Cantor Virtual Global Healthcare Conference
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Reports Second Quarter 2021 Financial Results
From Xencor, Inc.
Via Business Wire
News headline image
Xencor to Present at Upcoming Investor Conferences
From Xencor, Inc.
Via Business Wire
News headline image
Xencor to Host Second Quarter 2021 Financial Results Webcast and Conference Call on August 4, 2021
From Xencor, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.